Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins JCI Insight 2018, 3(11), e120631

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation.

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation. Ellis J, Neil D, Inston N, Jenkinson E, Drayson M, Hampson P, Shuttleworth S, Ready A, Cobbold M. Transplantation 2016, 100(8), 1667

Functional characterization of a novel somatic mutation of PIK3CB

Functional characterization of a novel somatic mutation of PIK3CB Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ Signal Transduction and Targeted Therapy 2017, volume 2, 17063

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma. Jain N., Seghal L., Shuttleworth S.J., Samaniego F. Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y.,  Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L. Abstract 1837. 58th ASH Annual Meeting and […]

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, […]

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P; Whale A., Shuttleworth S.J. In: Proceedings of the 107th Annual Meeting of […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Orlando)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander A., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. 57th ASH Annual Meeting and Exposition, Orlando, […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Brussels)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. EORTC-NCI-EMA-AACR Conference on Innovation and Biomarkers in […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, […]